ReviveMed ’s Post

I am thrilled to announce that our study, "Examining Response to Immunotherapy in Clear-Cell Renal Cell Carcinoma Using Baseline Serum Metabolic Signatures," is now available on the ASCO website: https://lnkd.in/grN5Hufx 🔬 Key Highlights: ✨ Innovative Algorithm - mzLearn: We've developed mzLearn, a data-driven algorithm that overcomes challenges in LC/MS measurements of untargeted metabolomics at scale. ✨ Significant Findings: We identified three main metabolomic subtypes with distinct progression-free survival (PFS) in response to treatments, providing crucial insights for clinical applications. ✨ Predictive Biomarkers: We discovered novel blood-based metabolic signatures that predict immunotherapy response at baseline, establishing a foundation for predictive biomarker discovery and therapeutic recommendations. Join us at #ASCO2024 to learn more about our findings and our #AI-based #metabolomics platform for #Precision #Medicine.